BioCentury | Oct 3, 2011
Company News

Aaraim Pharmaceuticals Inc., Nanotherapeutics, Neumedicines, RxBio, The University of Arkansas for Medical Sciences other news

...diethylenetriaminepentaacetate. Neumedicines received $17 million for HemaMax a recombinant human IL-12 in Phase I testing. RxBio...
...Pharmaceuticals Inc. , Ossining, N.Y. Nanotherapeutics Inc. , Alachua, Fla. Neumedicines Inc. , Pasadena, Calif. RxBio Inc....
BioCentury | Sep 30, 2011
Company News

BARDA awards up to $70.7M for radiation therapies

...chelating agent diethylenetriaminepentaacetate. Neumedicines Inc. (Pasadena, Calif.) received $17 million for HemaMax recombinant human IL-12. RxBio Inc....
BioCentury | Jan 22, 2007
Clinical News

RxBio preclinical data

...a radioprotectant that is a specific activator of natural, nontoxic protective mechanisms of cell survival. RxBio Inc....
Items per page:
1 - 3 of 3
BioCentury | Oct 3, 2011
Company News

Aaraim Pharmaceuticals Inc., Nanotherapeutics, Neumedicines, RxBio, The University of Arkansas for Medical Sciences other news

...diethylenetriaminepentaacetate. Neumedicines received $17 million for HemaMax a recombinant human IL-12 in Phase I testing. RxBio...
...Pharmaceuticals Inc. , Ossining, N.Y. Nanotherapeutics Inc. , Alachua, Fla. Neumedicines Inc. , Pasadena, Calif. RxBio Inc....
BioCentury | Sep 30, 2011
Company News

BARDA awards up to $70.7M for radiation therapies

...chelating agent diethylenetriaminepentaacetate. Neumedicines Inc. (Pasadena, Calif.) received $17 million for HemaMax recombinant human IL-12. RxBio Inc....
BioCentury | Jan 22, 2007
Clinical News

RxBio preclinical data

...a radioprotectant that is a specific activator of natural, nontoxic protective mechanisms of cell survival. RxBio Inc....
Items per page:
1 - 3 of 3